Claryx Secures $3.5M to Transform Hospital Infection Prevention
August 9, 2026, 9:33 am
Location: United States, California, San Francisco
Employees: 1-10
Founded date: 2015
Claryx, a new genomic intelligence startup, has emerged with $3.5M in pre-seed funding. Its mission: transform hospital infection prevention. The platform reads pathogen genomes, linking patient cases to environmental sources. It builds a "digital twin" of hospital buildings, mapping air, water, and surface pathogens. This innovative system identifies outbreaks before they spread. It enhances patient safety, reduces healthcare-associated infections, and lowers operational costs. Claryx offers a continuous, proactive surveillance solution, driven by proprietary, cost-effective sequencing. The technology marks a significant leap in preventing disease transmission within healthcare settings.
Hospitals face a persistent enemy. Healthcare-associated infections (HAIs) plague facilities worldwide. These infections cause severe patient harm. They drive up healthcare costs. Current surveillance often falls short. It is frequently reactive. Outbreaks spread before detection. Claryx now offers a powerful new weapon. The company secured $3.5 million in pre-seed funding. It aims to build an immune system for hospitals. This system employs genomic intelligence. It stops outbreaks before they escalate.
The funding round saw strong support. Outlander VC led the investment. Participation came from Company Ventures, Boost VC, Neon, Mana Ventures, 640 Oxford, and Precursor. This capital fuels Claryx's mission. It will expand operations. Research and development efforts will accelerate. The goal is clear: prevent infections.
Claryx’s innovation stems from a deeply personal experience. Founders Kurt and Dirk Hackenberger are brothers. Their grandmother contracted *C. difficile* in a hospital. This devastating infection led to sepsis. Her family never received answers. Where did the infection originate? This question drives Claryx. They seek to provide those answers.
Traditional infection control struggles with this challenge. Hospitals identify individual cases well. Connecting those cases proves much harder. Patients infected on different floors appear unrelated. Cases scattered over time evade detection. Standard surveillance relies on rising case counts. Small, dispersed clusters often go unnoticed. They never trigger an alarm.
Genomic sequencing changes everything. It offers a new lens. Pathogens possess genetic fingerprints. These fingerprints reveal connections. Infection prevention teams can link seemingly unrelated cases. They identify shared transmission chains. This insight uncovers outbreaks sooner. It helps pinpoint sources. It also verifies intervention effectiveness.
Claryx pushes this technology further. It makes surveillance continuous. Hospitals no longer wait for obvious outbreaks. They proactively seek hidden ones. The scale of HAIs is immense. One in 38 U.S. hospital patients contracts an HAI daily. These infections cost billions annually. They extend hospital stays. Bed capacity is already tight. Hospitals also face financial penalties. Poor HAI performance can reduce Medicare payments. Claryx bets on early detection. It can change this grim equation.
The CloneLink platform stands at the core of Claryx’s solution. It integrates two powerful components. First, genomic sequencing of patient infections. Second, a "digital twin" of the hospital environment. This digital twin is critical. It maps pathogens in air, water, and on surfaces. Claryx sequences samples from these common hiding spots. Then, it compares patient pathogens to environmental samples. This comparison reveals environmental reservoirs. A contaminated sink or equipment can be identified. Genomic matches provide strong clues.
The historical barrier to this approach was cost. Broad, continuous sequencing was prohibitive. Dirk Hackenberger addressed this. His doctoral research yielded proprietary chemistry. This innovation drastically reduces sequencing costs. It cuts the most expensive step by over twentyfold. This cost reduction is central to Claryx’s pitch. Sequencing becomes affordable. Genomic surveillance shifts from reactive investigation to proactive detection. Hospitals can ask: Are these isolated cases connected?
Real-world evidence supports this vision. A two-year study at UPMC Presbyterian demonstrated the potential. Researchers used real-time whole-genome sequencing surveillance. The study identified 172 outbreaks. These involved 476 patients. Traditional methods would have missed them. Interventions based on genomic investigation proved highly effective. They stopped further transmission in 96% of cases. The program prevented 62 infections. It saved nearly five lives over two years. Economic analysis showed a 3.2-fold return on investment.
These findings are profound. Hospitals likely harbor more small outbreaks than perceived. Conventional systems miss these. They remain buried in normal infection numbers. Genomics provides a vital new signal. Claryx wants to make this signal infrastructure.
The Hackenberger brothers bring diverse expertise. Dirk, the CSO, is a scientist. His PhD focused on infectious disease genomics. He studied antimicrobial resistance. His research appeared in top scientific journals. Kurt, the CEO, comes from finance. He was an investor at The Carlyle Group. He led diligence for hundreds of companies. He participated in billions in investments. Their combined backgrounds perfectly suit the problem. They share a common goal. Preventable infections are solvable.
Claryx technology is already deployed. It is live across multiple health systems. The ambition extends beyond individual outbreaks. Claryx aims for a dynamic map. It shows pathogen movement through buildings. A scientific advisory board supports this effort. It includes clinicians and researchers. Experts from Mayo Clinic, Harvard, Yale, and the CDC are involved.
Outlander VC sees a grander opportunity. Hospitals are a starting point. But the technology's reach is wider. "Every building people share is a transmission system," stated an Outlander partner. "Claryx has made it possible to finally see it." Hospitals are ideal initial targets. They concentrate vulnerable patients, pathogens, and movement. They also have strong incentives to reduce infections.
The core challenge remains. Can Claryx scale continuous genomic surveillance? Sequencing costs have plummeted. Transforming vast genomic data into actionable information is complex. Hospitals need fast, clear, trustworthy results. The system must be inexpensive enough for daily use.
Claryx’s $3.5 million funding is modest by some standards. Yet, its potential impact is massive. Every infection avoided saves lives. It reduces hospital days. It lowers antibiotic use. It cuts treatment costs. For the Hackenberger brothers, it closes a twenty-two-year-old question. Where did the infection come from? Claryx offers the tools to answer it. It provides the means to prevent the next one. This technology marks a new era in hospital safety. It prioritizes proactive disease control.
Hospitals face a persistent enemy. Healthcare-associated infections (HAIs) plague facilities worldwide. These infections cause severe patient harm. They drive up healthcare costs. Current surveillance often falls short. It is frequently reactive. Outbreaks spread before detection. Claryx now offers a powerful new weapon. The company secured $3.5 million in pre-seed funding. It aims to build an immune system for hospitals. This system employs genomic intelligence. It stops outbreaks before they escalate.
The funding round saw strong support. Outlander VC led the investment. Participation came from Company Ventures, Boost VC, Neon, Mana Ventures, 640 Oxford, and Precursor. This capital fuels Claryx's mission. It will expand operations. Research and development efforts will accelerate. The goal is clear: prevent infections.
Claryx’s innovation stems from a deeply personal experience. Founders Kurt and Dirk Hackenberger are brothers. Their grandmother contracted *C. difficile* in a hospital. This devastating infection led to sepsis. Her family never received answers. Where did the infection originate? This question drives Claryx. They seek to provide those answers.
Traditional infection control struggles with this challenge. Hospitals identify individual cases well. Connecting those cases proves much harder. Patients infected on different floors appear unrelated. Cases scattered over time evade detection. Standard surveillance relies on rising case counts. Small, dispersed clusters often go unnoticed. They never trigger an alarm.
Genomic sequencing changes everything. It offers a new lens. Pathogens possess genetic fingerprints. These fingerprints reveal connections. Infection prevention teams can link seemingly unrelated cases. They identify shared transmission chains. This insight uncovers outbreaks sooner. It helps pinpoint sources. It also verifies intervention effectiveness.
Claryx pushes this technology further. It makes surveillance continuous. Hospitals no longer wait for obvious outbreaks. They proactively seek hidden ones. The scale of HAIs is immense. One in 38 U.S. hospital patients contracts an HAI daily. These infections cost billions annually. They extend hospital stays. Bed capacity is already tight. Hospitals also face financial penalties. Poor HAI performance can reduce Medicare payments. Claryx bets on early detection. It can change this grim equation.
The CloneLink platform stands at the core of Claryx’s solution. It integrates two powerful components. First, genomic sequencing of patient infections. Second, a "digital twin" of the hospital environment. This digital twin is critical. It maps pathogens in air, water, and on surfaces. Claryx sequences samples from these common hiding spots. Then, it compares patient pathogens to environmental samples. This comparison reveals environmental reservoirs. A contaminated sink or equipment can be identified. Genomic matches provide strong clues.
The historical barrier to this approach was cost. Broad, continuous sequencing was prohibitive. Dirk Hackenberger addressed this. His doctoral research yielded proprietary chemistry. This innovation drastically reduces sequencing costs. It cuts the most expensive step by over twentyfold. This cost reduction is central to Claryx’s pitch. Sequencing becomes affordable. Genomic surveillance shifts from reactive investigation to proactive detection. Hospitals can ask: Are these isolated cases connected?
Real-world evidence supports this vision. A two-year study at UPMC Presbyterian demonstrated the potential. Researchers used real-time whole-genome sequencing surveillance. The study identified 172 outbreaks. These involved 476 patients. Traditional methods would have missed them. Interventions based on genomic investigation proved highly effective. They stopped further transmission in 96% of cases. The program prevented 62 infections. It saved nearly five lives over two years. Economic analysis showed a 3.2-fold return on investment.
These findings are profound. Hospitals likely harbor more small outbreaks than perceived. Conventional systems miss these. They remain buried in normal infection numbers. Genomics provides a vital new signal. Claryx wants to make this signal infrastructure.
The Hackenberger brothers bring diverse expertise. Dirk, the CSO, is a scientist. His PhD focused on infectious disease genomics. He studied antimicrobial resistance. His research appeared in top scientific journals. Kurt, the CEO, comes from finance. He was an investor at The Carlyle Group. He led diligence for hundreds of companies. He participated in billions in investments. Their combined backgrounds perfectly suit the problem. They share a common goal. Preventable infections are solvable.
Claryx technology is already deployed. It is live across multiple health systems. The ambition extends beyond individual outbreaks. Claryx aims for a dynamic map. It shows pathogen movement through buildings. A scientific advisory board supports this effort. It includes clinicians and researchers. Experts from Mayo Clinic, Harvard, Yale, and the CDC are involved.
Outlander VC sees a grander opportunity. Hospitals are a starting point. But the technology's reach is wider. "Every building people share is a transmission system," stated an Outlander partner. "Claryx has made it possible to finally see it." Hospitals are ideal initial targets. They concentrate vulnerable patients, pathogens, and movement. They also have strong incentives to reduce infections.
The core challenge remains. Can Claryx scale continuous genomic surveillance? Sequencing costs have plummeted. Transforming vast genomic data into actionable information is complex. Hospitals need fast, clear, trustworthy results. The system must be inexpensive enough for daily use.
Claryx’s $3.5 million funding is modest by some standards. Yet, its potential impact is massive. Every infection avoided saves lives. It reduces hospital days. It lowers antibiotic use. It cuts treatment costs. For the Hackenberger brothers, it closes a twenty-two-year-old question. Where did the infection come from? Claryx offers the tools to answer it. It provides the means to prevent the next one. This technology marks a new era in hospital safety. It prioritizes proactive disease control.